Home Blog of Signal Transduction PI3K/Akt/mTOR PI3K SGK3 and INPP4B mediate PI3K signaling pathway in breast cancer

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

SGK3 and INPP4B mediate PI3K signaling pathway in breast cancer

 

Phosphoinositide 3-kinase (PI3K) is a well-known mediator in breast cancer by increasing cell proliferation rate, survival, and metastasis level. The oncogenic mutations in the gene encoding PI3K catalytic subunit, PI3KCA, are frequently happened in breast cancers. By investigating the mechanism of PIK3CA signaling transduction, Gasser et al.  found serum/glucocorticoid-regulated kinase 3 (SGK3) and inositol polyphosphate-4-phosphatase type II (INPP4B) are two critical factors in tumors with PIK3CA mutations. Recently, the article was published online by Molecular Cell

 

Akt is considered to be a primary target of the PI3K signal. However, researchers found PI3K mediated PI3KCA-mutant tumorigenic signals in an Akt-independent manner. SGK3 was found to be the downstream factor of PIK3CA. The activation of SGK3 was dependent on INPP4B, which suppressed Akt phosphorylation. Further investigation showed N-Myc downstream regulated 1 (NDRG1) is a downstream signal of SGK3 in breast cancer cells. This work provides a new insight into PI3K signaling axis, with SGK3 and INPP4B as key factors and in the absence of Akt activity, for regulation of tumorigenesis, tumor cell proliferation and invasive migration.

 

Reference:
Mol Cell. 2014 Nov 20;10.1016/j.molcel.2014.09.023

Related Products

Cat.No. Product Name Information
S2247 Buparlisib (BKM120) Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.
S1039 Rapamycin Rapamycin is a specific mTOR inhibitor with IC50 of ~0.1 nM in HEK293 cells.Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator and an immunosuppressant.

Related Targets

PI3K Akt mTOR